Quarterly report pursuant to Section 13 or 15(d)

Merger with Private Molecular - Additional Information (Detail)

v3.10.0.1
Merger with Private Molecular - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Aug. 01, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 30, 2018
Jun. 30, 2017
Jun. 01, 2017
Mar. 24, 2017
Business Acquisition [Line Items]              
Exercise price per share on stock options after reverse stock split       $ 7.06      
Stock compensation   $ 922,000 $ 25,000 $ 1,565,000 $ 52,000    
2014 Equity Incentive Plan              
Business Acquisition [Line Items]              
Stock compensation       $ 1,200,000      
Threshold              
Business Acquisition [Line Items]              
Common stock shares issued in exchange of each share 7.7844            
Threshold equity holders ownership interest 34.40%            
Private Molecular equity holders ownership interest 65.60%            
Stock option outstanding to purchase common stock 963,681            
Number of vested stock option shares after reverse stock split 963,681            
Exercise price per share on stock options after reverse stock split $ 33.62            
Fair value inputs discount rate 12.00%            
Transaction costs associated with Merger $ 2,000,000            
Principal amount           $ 2,000,000 $ 2,000,000
Promissory note interest rate             1.00%